Its great to see management at MYX not only look at large acquisitions such as Metrics and Kapanol but smaller opportunities as well.
What I like about the Libertas acquisition is a three year performance based earn-out which will be funded from operating cash where 60% of the total purchase price will be performance base as well as a payment of 503,493 Shares issued to Chris Schneider at 43 cents or $216,501.99.
I also like the idea the owner founder will be joining Mayne Pharma’s US Leadership team as Vice President, Sales & Marketing, who else would be better equipped to know and understand their products than the current owner.
The buy side looking very strong today with some good buying, the market seems to like the deal and the lower Australian dollar and you would expect it will go lower over the next couple of months which will bode well for MYX.
Cheers Matsim
acquisition, page-3
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.73 |
Change
0.140(3.05%) |
Mkt cap ! $402.4M | |||
| Open | High | Low | Value | Volume |
| $4.59 | $4.73 | $4.54 | $464.8K | 99.77K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 111 | $4.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.73 | 9143 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |